Mifepristone Ruling Casts ‘Shadow Of Uncertainty’ Over All FDA Approvals, Drug Industry Tells Supreme Court
Executive Summary
As Supreme Court term begins, PhRMA and host of pharma CEOs and investors implore justices to take up mifepristone case to prevent chaos for drug development. High court also will consider lawsuit challenging deference to federal rulemaking and may consider another that would increase corporate liability under Anti-Terrorism Act.